Acurx Pharma raises $2.67M via warrant exercise; issues new warrants for ~8.89M shares

Acurx Pharmaceuticals, Inc.

Entered warrant inducement agreement; holder exercised ~4.45M existing warrants at reduced $0.60/share, gross proceeds $2.67M.
Net proceeds ~$2.3M after fees; used for working capital and general corporate purposes.
Issued new G-1 and G-2 warrants to purchase up to 8,890,870 shares at $0.425/share; G-1 exercisable immediately, G-2 upon shareholder approval.
H.C. Wainwright gets 7% fee and warrants to purchase 266,726 shares at $0.75/share.
Expected close June 20, 2025; 45-day stock issuance restriction and 90-day variable rate transaction restriction.

item 1.01item 3.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.